“The Acute Myeloid Leukemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics”

 

The Acute Myeloid Leukemia market report provides current treatment practices, Acute Myeloid Leukemia emerging drugs, market share of individual therapies, and current and forecasted 7MM Acute Myeloid Leukemia market size from 2019 to 2032. The report also covers current Acute Myeloid Leukemia treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Acute Myeloid Leukemia Market Research Report

• The total number of Acute Myeloid Leukemia incident cases associated with 7MM countries was 41,715 in 2020.
• The current understanding of Acute Myeloid Leukemia has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.
• According to DelveInsight’s analysis, acute myeloid leukemia (AML) is more prominent in males in comparison to females.
• The leading companies working in the Acute Myeloid Leukemia Market include Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
• Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include Daurismo (Glasdegib), VENCLEXTA (Venetoclax), ASTX727 [Decitabine and cedazuridine], Dociparstat sodium (DSTAT, CX-01), and others.
• September 2023: AbbVie announced a study of phase 3 clinical trials for Venetoclax, Azacitidine, and CC-486. This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with AZA. Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with CC-486.
• September 2023: Astellas Pharma Global Development Inc. announced a study of phase 1 & 2 clinical trials for Gilteritinib, Venetoclax,  and Azacitidine. The main aims of this study are: to find suitable doses of gilteritinib, venetoclax and azacitidine as a combined treatment; to learn how they are processed by and act upon the body; to learn the remission rate; to check for medical problems during this treatment.

 

Discover more about therapies set to grab major Acute Myeloid Leukemia Market Share @ Acute Myeloid Leukemia Market Size

 

Acute Myeloid Leukemia Overview

Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, which are responsible for producing red blood cells, white blood cells, and platelets.

 

Acute Myeloid Leukemia Epidemiology Segmentation in the 7MM

• Acute Myeloid Leukemia Gender-specific cases
• Acute Myeloid Leukemia Age-specific Cases
• Acute Myeloid Leukemia Genetic Mutations

 

Download the report to understand which factors are driving Acute Myeloid Leukemia Epidemiology Trends @ Acute Myeloid Leukemia Epidemiological Insights

 

Acute Myeloid Leukemia Emerging Drug

• Devimistat (CPI-613): Rafael Pharmaceuticals Inc.
• Crenolanib: Arog Pharmaceuticals

 

Acute Myeloid Leukemia Treatment Market

Acute Myeloid Leukemia treatment of most patients typically consists of two chemotherapy phases: remission induction (often just called induction) and consolidation (postremission therapy). There has been a plethora of drugs approved for this aggressive cancer, since 2017. The US FDA has approved glasdegib, venetoclax, ivosidenib, midostaurin, CPX- 351, and gemtuzumab ozogamicin (GO) to treat persons with newly diagnosed acute myeloid leukemia. Likewise, the European Medicines Agency (EMA) has approved midostaurin, CPX-351, and GO.   

 

To learn more about Acute Myeloid Leukemia Treatment options, visit @ Acute Myeloid Leukemia Drugs

 

Acute Myeloid Leukemia Market Size

DelveInsight’s analysts estimate that Acute Myeloid Leukemia market is poised to show significant growth, mainly attributed to increasing incidence, recent drug approvals, and anticipated launch of novel therapies during the forecast period (2019–2032). Various new therapies are in development, with a focus on mentioned limitations of the currently approved drugs. Some of the most prominent ones include ASTX 727 (Astex Pharmaceutical), Dociparstat Sodium (Chimerix), IO-202 (Immune Onc), among others.

 

Acute Myeloid Leukemia Market Outlook

The Acute Myeloid Leukemia market outlook presents a complex landscape shaped by ongoing research, technological advancements, and evolving treatment strategies. Acute Myeloid Leukemia, a rapidly progressing blood cancer affecting myeloid cells, continues to be a focus of intensive research and development within the pharmaceutical and biotechnology sectors. The Acute Myeloid Leukemia market outlook is marked by a surge in innovative therapies, including targeted treatments and immunotherapies, aiming to improve patient outcomes and enhance overall survival rates.

 

Learn more about the Acute Myeloid Leukemia Pipeline Therapies in clinical trials @ Acute Myeloid Leukemia Market Landscape

 

Scope of the Acute Myeloid Leukemia Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Acute Myeloid Leukemia Companies- Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
• Acute Myeloid Leukemia Pipeline Therapies- Daurismo (Glasdegib), VENCLEXTA (Venetoclax), ASTX727 [Decitabine and cedazuridine], Dociparstat sodium (DSTAT, CX-01), and others.
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia Market Drivers and Barriers
• Acute Myeloid Leukemia Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Acute Myeloid Leukemia Drugs in development @ Acute Myeloid Leukemia Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Executive Summary of Acute Myeloid Leukemia (AML)

3. Competitive Intelligence Analysis for Acute Myeloid Leukemia (AML)

4. Acute Myeloid Leukemia (AML): Market Overview at a Glance

5. Acute Myeloid Leukemia (AML): Disease Background and Overview

6. Patient Journey

7. Acute Myeloid Leukemia (AML) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Myeloid Leukemia (AML) Unmet Needs

10. Key Endpoints of Acute Myeloid Leukemia (AML) Treatment

11. Acute Myeloid Leukemia (AML) Marketed Products

12. Acute Myeloid Leukemia (AML) Emerging Therapies

13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acute Myeloid Leukemia Market Outlook

16. Acute Myeloid Leukemia Market Access and Reimbursement Overview

17. Acute Myeloid Leukemia KOL Views

18. Acute Myeloid Leukemia Market Drivers

19. Acute Myeloid Leukemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking